Vridapa is a combination medication that contains two active ingredients: dapagliflozin and sitagliptin. It is used to help manage type 2 diabetes in adults by addressing high blood sugar levels through two complementary mechanisms. This combination offers the benefit of improved glucose control while also supporting heart and kidney health in certain patients. Vridapa is usually prescribed when lifestyle changes and single-drug treatments are not enough.

Mechanism of Action:
This dual-action medicine works through the combined effects of its two components:

• Dapagliflozin is an SGLT2 inhibitor. It helps the kidneys remove excess sugar from the blood by increasing the amount of glucose passed out in the urine.

• Sitagliptin is a DPP-4 inhibitor. It works by increasing levels of hormones that stimulate insulin release and decrease sugar production by the liver, particularly after meals.

  Uses:
  Vridapa is prescribed for the treatment of:

  • Type 2 diabetes in adults who need better blood sugar control

  • Patients who may benefit from additional cardiovascular or kidney protection

  • Individuals who are not adequately managed on metformin or other single-drug treatments

    Adverse Effects:
    Vridapa is usually well tolerated, but some individuals may experience side effects. These can include:

    • Increased urination

    • Genital or urinary tract infections due to excess glucose in urine

    • Headache, nausea, or upset stomach

    • Low blood sugar, especially when used with other diabetes medications

    • Dehydration or dizziness due to fluid loss

    • Rarely, pancreatitis or serious allergic reactions